Esketamine Nasal Spray: Rapid Relief for TRD and Suicide Prevention-Mechanisms and Pharmacodynamics.
Hui Song, Yang Luo, Lingzhi Fang
Neuropsychiatric disease and treatment January 1, 2024 DOI: 10.2147/NDT.S486118 via PubMed
Summary
AI-generated from the abstractEsketamine nasal spray provides rapid relief for treatment-resistant depression (TRD) and helps prevent suicidal behavior. It works primarily by blocking NMDA receptors in the brain, with additional effects on AMPA receptors, opioid receptors, monoaminergic receptors, and inflammatory pathways, though the full synergistic mechanisms are not yet understood. Multiple randomized controlled trials show that esketamine reduces depressive symptoms within hours and maintains these benefits over several weeks, with a favorable safety profile and minimal side effects in long-term use. Its approval offers a new therapeutic option for patients with severe depression, impacting healthcare practices and policies.
Study at a glance
| Characteristics | Review Randomized Peer reviewed |
|---|---|
| Intervention | Esketamine nasal spray |
| Topics | Depression Esketamine |
| Keywords | Nmda receptors Trd Clinical benefits Pharmacodynamics |
| Key finding | Esketamine nasal spray effectively alleviates depressive symptoms and prevents suicidal behavior in treatment-resistant depression patients within hours, with sustained benefits over weeks and a good long-term safety profile. |
Abstract
Esketamine nasal spray has emerged as a promising rapid-relief therapy for treatment-resistant depression (TRD) and suicide prevention. This review examines the chemical structure and pharmacodynamics of esketamine, highlighting its primary action on NMDA receptors and additional effects on AMPA receptors, opioid receptors, monoaminergic receptors, and inflammatory pathways. Despite the synergistic mechanisms contributing to its clinical benefits not being fully understood, future studies are essential to refine our understanding and optimize clinical use. Clinical research indicates that esketamine effectively alleviates depressive symptoms and prevents suicidal behavior in TRD patients, demonstrating good safety and efficacy over extended periods. Specifically, multiple randomized controlled trials have shown that esketamine reduces depressive symptoms within hours and maintains these benefits over several weeks, with a favorable safety profile and minimal side effects observed in long-term use. The approval of esketamine for TRD has significant implications for healthcare practices and policies, offering a new therapeutic option that addresses the urgent needs of patients with severe depression.